IRMD vs. LIVN, ENOV, NVCR, WRBY, SSII, CNMD, LMAT, TNDM, EYE, and CDRE
Should you be buying Iradimed stock or one of its competitors? The main competitors of Iradimed include LivaNova (LIVN), Enovis (ENOV), NovoCure (NVCR), Warby Parker (WRBY), SS Innovations International (SSII), CONMED (CNMD), LeMaitre Vascular (LMAT), Tandem Diabetes Care (TNDM), National Vision (EYE), and Cadre (CDRE). These companies are all part of the "medical equipment" industry.
Iradimed vs.
LivaNova (NASDAQ:LIVN) and Iradimed (NASDAQ:IRMD) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.
97.6% of LivaNova shares are owned by institutional investors. Comparatively, 92.3% of Iradimed shares are owned by institutional investors. 0.3% of LivaNova shares are owned by company insiders. Comparatively, 36.8% of Iradimed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, LivaNova had 15 more articles in the media than Iradimed. MarketBeat recorded 17 mentions for LivaNova and 2 mentions for Iradimed. Iradimed's average media sentiment score of 1.83 beat LivaNova's score of 1.33 indicating that Iradimed is being referred to more favorably in the news media.
LivaNova received 148 more outperform votes than Iradimed when rated by MarketBeat users. Likewise, 69.80% of users gave LivaNova an outperform vote while only 65.58% of users gave Iradimed an outperform vote.
LivaNova has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, Iradimed has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500.
LivaNova currently has a consensus price target of $59.29, indicating a potential upside of 35.90%. Iradimed has a consensus price target of $72.00, indicating a potential upside of 36.08%. Given Iradimed's higher possible upside, analysts plainly believe Iradimed is more favorable than LivaNova.
Iradimed has lower revenue, but higher earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Iradimed, indicating that it is currently the more affordable of the two stocks.
Iradimed has a net margin of 26.26% compared to LivaNova's net margin of 1.91%. Iradimed's return on equity of 24.12% beat LivaNova's return on equity.
Summary
Iradimed beats LivaNova on 10 of the 18 factors compared between the two stocks.
Get Iradimed News Delivered to You Automatically
Sign up to receive the latest news and ratings for IRMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Iradimed Competitors List
Related Companies and Tools
This page (NASDAQ:IRMD) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy IRMD Stock Free IRMD Stock Alerts